NASDAQ$ANNX
Annexon Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Annexon reported second quarter financial results and provided a mid-year business update.
Annexon reported a net loss of $31.3 million for the second quarter of 2021, with research and development expenses at $24.6 million and general and administrative expenses at $6.8 million. Cash and cash equivalents totaled $302.4 million as of June 30, 2021.
- Expanded autoimmune franchise with advancement of ANX009 and strategic expansion into autoantibody-driven diseases.
- Continued progress in neurodegeneration franchise with Phase 2 data from ANX005 in Huntington’s disease expected in Q4 2021 and initiation of Phase 2 ANX005 trial in Amyotrophic Lateral Sclerosis.
- Appointed William D. Waddill to the Board of Directors.
- Progressed enrollment in multiple Phase 2/3 trials across autoimmune and ophthalmology franchises.
Headline financials
Revenue & EPS history
Annexon · Revenue · Quarterly
$0
Forward guidance
Annexon is focused on advancing its clinical programs and expects to report data from multiple clinical trials and peer-reviewed forums in the coming months.
Tailwinds
- ANX005 Phase 2/3 trial in Guillain-Barré Syndrome (GBS) remains on track for completion in 2023.
- Phase 2 trial of ANX005 in warm autoimmune hemolytic anemia (wAIHA) is advancing with data expected to be submitted to a peer reviewed forum in 2021.
- Phase 2 study of ANX005 in Multifocal Motor Neuropathy (MMN) is anticipated to begin in early 2022.
- Phase 1b study of ANX009 in Lupus Nephritis (LN) is anticipated to begin in early 2022.
- Initial data from Phase 2 trial of ANX005 in Huntington’s Disease (HD) is expected in Q4 2021.
Headwinds
- Phase 2 trial of ANX005 in Amyotrophic Lateral Sclerosis (ALS) data is now expected in 2022 due to slower initial enrollment.
- Potential risks and uncertainties related to clinical development and regulatory approvals.
- Reliance on third-party suppliers and manufacturers poses a risk.
- Outcomes of future collaboration agreements are uncertain.
- The company's ability to maintain intellectual property rights for its product candidates is not guaranteed.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+3.0%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+1.8%
Avg return
30 days after
64%
14 / 22 earnings
Positive
+23.1%
Q1 2022
Best reaction
-8.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -6.9% | -4.6% | -7.4% | |
| Q3 2025 | -0.7% | -9.1% | +69.1% | |
| Q1 2025 | +9.4% | +8.8% | +37.6% | |
| Q4 2024 | +3.3% | +15.5% | -23.4% | |
| Q3 2024 | -6.6% | -16.6% | -32.2% | |
| Q2 2024 | +3.8% | +11.3% | +12.8% | |
| Q1 2024 | +1.5% | -8.8% | +27.2% | |
| Q4 2023 | +17.6% | +8.0% | -30.9% | |
| Q3 2023 | +16.7% | +22.4% | +23.8% | |
| Q2 2023 | -1.2% | -2.1% | -26.6% | |
| Q1 2023 | +4.2% | +3.7% | -40.7% | |
| Q4 2022 | +3.8% | -8.0% | -15.0% | |
| Q3 2022 | -0.4% | +16.6% | +15.8% | |
| Q2 2022 | +3.1% | +17.2% | +10.2% | |
| Q1 2022 | +23.1% | +25.0% | +51.2% | |
| Q4 2021 | -5.1% | -11.0% | -43.8% | |
| Q3 2021 | +1.3% | +0.2% | -3.4% | |
| Q2 2021 | -4.6% | -13.7% | +11.6% | |
| Q1 2021 | +1.1% | +9.3% | +12.6% | |
| Q4 2020 | -8.1% | -17.4% | -29.5% | |
| Q3 2020 | +3.5% | +9.1% | +13.0% | |
| Q2 2020 | +6.6% | -1.2% | +8.9% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro